Gelareh Eslamian

Gelareh Eslamian

Auto-generated profile, based on publicly available information

Gelareh Eslamian

Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
GEGelareh Eslamian
Gelareh Eslamian
CWCaroline Wilson
Caroline Wilson
RYRobin J Young
Robin J Young
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial–mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.

22 October 2020 in Drug and Therapeutics Bulletin
Verified
Journal Article
Closed access
PDF file
DHDaisy Henderson
Daisy Henderson
GEGelareh Eslamian
Gelareh Eslamian
DPDaniel Poon
Daniel Poon
SCSimon J. Crabb
Simon J. Crabb
RJRobert Jones
Robert Jones
DJDebra Josephs
Debra Josephs
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).